

**EFFICACY OF INTRAVENOUS
IMMUNOGLOBULIN IN Rh HEMOLYTIC
ANEMIA OF NEWBORN**

Thesis

Submitted in Partial Fulfillments for Mater Degree
In Pediatrics

By

Heba Wegdan Abaza

M.B.B.Ch.

Faculty of Medicine

Under Supervision of

Prof. Dr. Mohsen Saleh El Alfy

Professor of Pediatrics

Faculty of Medicine – Ain Shams University

Dr. Nancy Samir El-Barbary

Lecturer of Pediatrics

Faculty of Medicine – Ain Shams University

Faculty of Medicine

Ain Shams University

2010



قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْحَكِيمُ

صدق الله العظيم
سورة البقرة الآية (32)

Acknowledgement

First and foremost I feel always indebted to ALLAH, the Most Beneficent and Merciful

I would like to express my appreciations to Prof. Dr. Mohsen Saleh El Alfy, Professor of Pediatrics, Faculty of Medicine, Ain Shams University, for his valuable recommendations for me.

I would like to thank Dr. Nancy El Barbary, Lecturer of Pediatrics, Faculty of Medicine, Ain Shams University, for her great support, patience and supervision.

Last but not least I would like to thank the parents of my patients for their co-operations.

*Heba Wegdan Abaza
M.B., B.Ch.*

Dedication

I would like to thank
my great mother and father
for their love and care.

I would like to thank
my husband for his great
support and love, and my
son for his patience.

I would like to thank
my sisters for their
encouragement and love.

List of Contents

	<i>Page</i>
List of abbreviations	I
List of tables	IV
List of figures	VI
Introduction and Aim of work	1
Review of Literature:	
○ Chapter (1): Neonatal Jaundice	5
○ Chapter (2): Intravenous Immunoglobulin	82
Patients and Methods	98
Results	106
Discussion	126
Summary and Conclusion	141
Recommendations	145
References	146
Arabic summary	—

List of Abbreviations

2,3-DBG .. 2,3-Diphosphoglycerate

AAP American Academy of Pediatrics

ABE Acute Bilirubin Encephalopathy

ALAT Alanine Aminotransferase

ASAT Aspartate Aminotransferase

ATP Adenosine Triphosphate

BA Biliary Atresia

BAER Brain Stem Auditory Evoked Responses

BCR B Cell Receptor

BIND Bilirubin Induced Neurological Dysfunction

CBC Complete Blood Count

CMOAT .. Canalicular Multispecific Organic Anion Transporter

CMV Cytomegalovirus

CNSHA ... Chronic Nonspherocytic Hemolytic Anemia

CO Carbon Monoxide

COPD Chronic Obstructive Pulmonary disease

DAT Direct Antibody Test

ER Endoplasmic Reticulum

ERCP Endoscopic Retrograde Cholangiopancreatography

ETCO End-Tidal Carbon Monoxide in Breath

FAB Fragment Antigen Binding

FC Fragment Crystallizable

G6PD Glucose-6-Phosphate Dehydrogenase Deficiency

GGT G-Glutamyltransferase

GST Glutathione S-Transferases

HDN Hemolytic disease of the newborn

HE Hereditary Elliptocytosis

HIDA Hepatoiminodiacetic acid

HPV Human Papillomavirus

Ig G Immunoglobulin G

IgA Immunoglobulin A

IgD Immunoglobulin D

IgE Immunoglobulin E

IgM Immunoglobulin M

ITP Immune-Thrombocytopenic Purpura

IUGR Intra Uterine Growth Retardation

IVIG Intra Venous ImmunoGlobulin

LED Light-Emitting Diode

MRI Magnetic Resonant Imaging

PK Pyruvate Kinase

PUBS Percutaneous Umbilical Blood Sampling

RDS Respiratory Distress Syndrome

SGOT Serum Glutamic Oxaloacetic Transaminase

SGPT Serum Glutamic Pyruvic Transaminase

TCB Transcutaneous Bilirubinometry

List of Tables

<i>Table</i>	<i>Page</i>
Table (1): Congenital non hemolytic unconjugated hyperbilirubinemia: clinical syndromes	12
Table (2): Characteristic difference between Rh and ABO hemolytic disease of newborn	20
Table (3): Risk factors for development of severe hyperbilirubinemia in infants of 35 or more gestation	26
Table (4): Management of hyperbilirubinemia in healthy term newborn	32
Table (5): Management of hyperbilirubinemia in preterm newborn (sick and well)	33
Table (6): Comparison between the studied groups according to sex, mode of delivery, history of maternal diseases diabetes and history of other child jaundice	65
Table (7): Comparison between the studied groups regarding gestational age and birth weight	66

Table (8):	Comparison between the three groups regarding laboratory findings	69
Table (9):	The rate of decrement in total serum bilirubin in the three groups, on admission 24 hours, 48 hours, 72 hours and 96 hours after therapy	71
Table (10):	comparisons between the three groups regarding bilirubin level on admission and after 24, 48, 72, and 96 hours of treatment	72
Table (11):	Percentage of change in bilirubin level after 24 and 48 hours of treatment.....	74
Table (12):	Comparison between the three groups regarding duration of phototherapy	76
Table (13):	comparisons between the three groups regarding duration of phototherapy	77
Table (14):	Comparison between the three groups regarding hospital stay	79
Table (15):	comparisons between the three groups regarding duration of hospital stay	80
Table (16):	Comparison between the three groups regarding frequency of exchange transfusion	82

List of Figures

<i>Figure</i>	<i>Page</i>
Fig. (1): Normal bilirubin metabolism, and during phototherapy.....	28
Fig. (2): Schematic of antibody binding to an antigen	42
Fig. (3): An antibody digested by papain yields three fragments: two Fab fragments and one Fc fragment	47
Fig. (4): Comparison between the three studied groups regarding sex	67
Fig. (5): Comparison between the three groups regarding mode of delivery	68
Fig. (6): Comparison between the three groups regarding bilirubin level	75
Fig. (7): Comparison between the three groups regarding duration of phototherapy	78
Fig. (8): Comparison between the three groups regarding duration of hospital stay	81
Fig. (9): Comparison between the three groups regarding exchange transfusion.....	83

Appendix

<i>Figure</i>	<i>Page</i>
(1) AAP Guidelines for phototherapy treatment (AAP, 2004)	
(2) AAP Guidelines for exchange transfusion treatment (AAP, 2004)	

INTRODUCTION

Neonatal jaundice is one of the commonly seen neonatal problems, as it affects 60% of full term infants and 80% of preterm infants in the first 3 days of birth. Although transient, the condition account for up to 75% of hospital readmission in the first week after birth (**Kristin Melton et al., 1999**).

Neonatal jaundice secondary to isoimmune hemolytic anemia (Rh, ABO incompatibility) is a cause of high serum bilirubin level due to hemolysis of RBCs secondary to transplacental passage of antibodies. This lead to increased risk of acute bilirubin encephalopathy and kernicterus (**Borgard et al., 2006**).

Hemolytic anemia is an alloimmune condition that develops in a fetus when IgG molecules that has been produced by the mother and has passed through the placenta; attack the red blood cells in the fetal circulation. The red cells are broken down and the fetus develop anemia (**Aher et al., 2008**).

Hemolysis leads to elevated bilirubin levels and symptoms of jaundice increase within 24 hours after birth. Like any other severe neonatal jaundice, there is a possibility of acute or chronic kernicterus (**Kirk, 2008**).

One of the causes of hemolytic disease of the newborn is the Rh disease. This occur in a Rh positive baby blood group born to a Rh negative mother blood group (**Smits-Wintjens et al., 2008**).

The use of anti-D prophylaxis in Rhesus negative women has led to a marked decline in Rhesus sensitization and hemolytic disease of the newborn. However sensitization can occur despite anti-D immunoglobulin particularly if it is given too late or in insufficient dose after a large feto-maternal hemorrhage. Many patients in developing countries do not receive Rh prophylaxis due to inadequate care or inability to afford anti-D immunoglobulin (**Cortey et al., 2006**).

Exchange transfusion is sometimes needed beside the conventional therapy (phototherapy) as it corrects anemia associated with hemolysis and is effective in removing sensitized red blood cells before they are hemolyzed. It also removes about 60% of bilirubin from the plasma, resulting in a clearance of about 30 to 40 % of total bilirubin as it equilibrates with extravascular tissues. Exchange transfusion is not without risk. It carries a 5% risk of major morbidity and the risks associated with blood exposure, infants receiving exchange transfusion have increased risks of infection, NEC acidosis, hypocalcaemia, electrolyte abnormalities and air embolism (**Kristin Melton et al., 1999**).

In recent years, intravenous immunoglobulins (IVIG) have been successfully used in isoimmune hemolytic anemia (Rh-ABO incompatibility) (**Miqdad et al., 2004**).

IVIG was found to decrease hemolysis leading to reduction in serum bilirubin level. The immunoglobulin could act by occupying the FC receptors of reticuloendothelial cells preventing them from taking up and lysing antibody coated RBCs (**Mundy, 2005**).